

# Author Index Volume 11 (2012)

The issue number is given in front of the pagination

- Agostini, M., M.V. Enzo, C. Bedin, V. Belardinelli, E. Goldin, P. Del Bianco, E. Maschietto, E. D'Angelo, L. Izzi, A. Sacconi, G. Zavagno and D. Nitti, Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients (2,3) 89–98
- Ahmad, A.S., see Kim, D.C. (2,3) 75–88
- Altmeyer, P., see Sand, M. (6) 253–257
- Alver, A., see Mentese, A. (5) 191–195
- Ammori, B.J., see Khaled, Y.S. (5) 183–190
- Attia, F.M., A.M. Hassan, N.N. El-Maraghy and G.H. Ibrahim, Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy (1) 41–47
- Baine, M.J., M. Menning, L.M. Smith, K. Mallya, S. Kaur, S. Rachagani, S. Chakraborty, A.R. Sasson, R.E. Brand and S.K. Batra, Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer (1) 1–14
- Banerjee, S., see Khanra, K. (4) 155–160
- Baorong, S., see Lu, Y. (5) 219–226
- Batra, S.K., see Baine, M.J. (1) 1–14
- Bechara, F.G., see Sand, M. (6) 253–257
- Bedin, C., see Agostini, M. (2,3) 89–98
- Belardinelli, V., see Agostini, M. (2,3) 89–98
- Benzina, S., see Harquail, J. (6) 269–280
- Bhattacharya, C., see Khanra, K. (4) 155–160
- Bhattacharyya, N., see Khanra, K. (4) 155–160
- Birgisson, H., K. Jirström and U.-H. Stenman, Serum concentrations of human chorionic gonadotropin beta and its association with survival in patients with colorectal cancer (4) 173–181
- Block, T.M., see Liang, H. (4) 161–171
- Bondgaard, A.-L.R.Ø., T.T. Poulsen, H.S. Poulsen and B.G. Skov, Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung (2,3) 123–128
- Borel Rinkes, I.H.M., see Lodewijk, L. (6) 229–238
- Boštjančič, E., see Tajnik, M. (5) 197–208
- Brand, R.E., see Baine, M.J. (1) 1–14
- Cai, S., see Lu, Y. (5) 219–226
- Chakraborty, S., see Baine, M.J. (1) 1–14
- Charest, D., see Odjélé, A. (6) 245–252
- Chatterjee, M., G. Dyson, N.K. Levin, J.P. Shah, R. Morris, A. Munkarah and M.A. Tainsky, Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence (2,3) 59–73
- Chen, K., see Feng, X. (2,3) 99–106
- Cheng, S., see Feng, X. (2,3) 99–106
- Cho, S.H., see Kim, D.C. (2,3) 75–88
- Colombo, C., see Trojani, A. (1) 15–28
- Colosimo, A., see Trojani, A. (1) 15–28
- Cuzick, J.M., see Kim, D.C. (2,3) 75–88
- Cvejić, D., see Marečko, I. (1) 49–58
- D'Angelo, E., see Agostini, M. (2,3) 89–98
- Del Bianco, P., see Agostini, M. (2,3) 89–98
- Di Camillo, B., see Trojani, A. (1) 15–28
- Dragutinović, V., see Marečko, I. (1) 49–58
- Duffy, S., see Kim, D.C. (2,3) 75–88
- Dyson, G., see Chatterjee, M. (2,3) 59–73
- Elkord, E., see Khaled, Y.S. (5) 183–190
- El-Maraghy, N.N., see Attia, F.M. (1) 41–47
- Enzo, M.V., see Agostini, M. (2,3) 89–98
- Feitelson, M.A., see Wang, W. (1) 29–39
- Feng, X., K. Chen, S. Ye, H. Wang, G. Wei, W. Tan, S. Cheng, Y. Zhang, S. Liu and Y. Zhou, MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis (2,3) 99–106
- Fidan, E., see Mentese, A. (5) 191–195
- Gish, R., see Liang, H. (4) 161–171
- Glavač, D., see Tajnik, M. (5) 197–208
- Goldin, E., see Agostini, M. (2,3) 89–98

- Greco, A., see Trojani, A. (1) 15–28
- Hafner, J., see Liang, H. (4) 161–171
- Han, B., see Liu, H.Y. (2,3) 115–121
- Hao, J.-O., see Wang, F. (6) 259–267
- Harquail, J., S. Benzina and G.A. Robichaud, MicroRNAs and breast cancer malignancy: An overview of miRNA-regulated cancer processes leading to metastasis (6) 269–280
- Hassan, A.M., see Attia, F.M. (1) 41–47
- He, Z., see Xu, Q. (4) 147–153
- Hogan, N.M., M.R. Joyce and M.J. Kerin, MicroRNA expression in colorectal cancer (6) 239–243
- Hu, Y., see Wang, Y. (4) 129–137
- Ibrahim, G.H., see Attia, F.M. (1) 41–47
- Imai, K., see Minamiya, Y. (4) 139–146
- Ito, M., see Minamiya, Y. (4) 139–146
- Izzi, L., see Agostini, M. (2,3) 89–98
- Jiang, S., see Shu, G.-S. (2,3) 107–114
- Jingyan, G., see Lu, Y. (5) 219–226
- Jirstrom, K., see K. (4) 173–181
- Joyce, M.R., see Hogan, N.M. (6) 239–243
- Karahan, S.C., see Mentese, A. (5) 191–195
- Kaur, S., see Baine, M.J. (1) 1–14
- Kavgaci, H., see Mentese, A. (5) 191–195
- Kerin, M.J., see Hogan, N.M. (6) 239–243
- Khaled, Y.S., E. Elkord and B.J. Ammori, Macrophage Inhibitory Cytokine-1: A review of its pleiotropic actions in cancer (5) 183–190
- Khanra, K., K. Panda, C. Bhattacharya, A.K. Mitra, R. Sarkar, S. Banerjee and N. Bhattacharyya, Association between newly identified variant form of DNA polymerase beta $_{\Delta 208-304}$  and ovarian cancer (4) 155–160
- Kim, D.C., M.A. Thorat, M.R. Lee, S.H. Cho, N. Vasiljević, D. Scibior-Bentkowska, K. Wu, A.S. Ahmad, S. Duffy, J.M. Cuzick and A.T. Lorincz, Quantitative DNA methylation and recurrence of breast cancer: A study of 30 candidate genes (2,3) 75–88
- Kist, J.W., see Lodewijk, L. (6) 229–238
- Konno, H., see Minamiya, Y. (4) 139–146
- Kranenburg, O., see Lodewijk, L. (6) 229–238
- Lee, M.R., see Kim, D.C. (2,3) 75–88
- Levin, N.K., see Chatterjee, M. (2,3) 59–73
- Li, J., see Xu, Q. (4) 147–153
- Liang, H., T.M. Block, M. Wang, B. Nefsky, R. Long, J. Hafner, A.S. Mehta, J. Marrero, R. Gish and P.A. Norton, Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73 (4) 161–171
- Liu, C.X., see Liu, H.Y. (2,3) 115–121
- Liu, H.Y., C.X. Liu, B. Han, X.Y. Zhang and R.P. Sun, AEG-1 is associated with clinical outcome in neuroblastoma patients (2,3) 115–121
- Liu, S., see Feng, X. (2,3) 99–106
- Lodewijk, L., A.M. Prins, J.W. Kist, G.D. Valk, O. Kranenburg, I.H.M. Borel Rinkes and M.R. Vriens, The value of miRNA in diagnosing thyroid cancer: A systematic review (6) 229–238
- Lodola, M., see Trojani, A. (1) 15–28
- Long, R., see Liang, H. (4) 161–171
- Lorincz, A.T., see Kim, D.C. (2,3) 75–88
- Lu, Y., G. Jingyan, S. Baorong, J. Peng, Y. Xu and S. Cai, Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer (5) 219–226
- Mallya, K., see Baine, M.J. (1) 1–14
- Marečko, I., D. Cvejić, S. Tatić, V. Dragutinović, I. Paunović and S. Savin, Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma (1) 49–58
- Marques, M.E.A., see Paiva, C.E. (5) 209–217
- Marrero, J., see Liang, H. (4) 161–171
- Martino, S., see Trojani, A. (1) 15–28
- Maschietto, E., see Agostini, M. (2,3) 89–98
- Mehta, A.S., see Liang, H. (4) 161–171
- Menning, M., see Baine, M.J. (1) 1–14
- Mentese, A., E. Fidan, A.U. Sumer, S.C. Karahan, M. Sonmez, D. Us Altay, H. Kavgaci and A. Alver, Is SCUBE 1 a new biomarker for gastric cancer? (5) 191–195
- Minamiya, Y., H. Saito, M. Ito, K. Imai, H. Konno, N. Takahashi, S. Motoyama and J. Ogawa, Suppression of Zinc Finger Homeobox 3 expression in tumor cells decreases the survival rate among non-small cell lung cancer patients (4) 139–146
- Mitra, A.K., see Khanra, K. (4) 155–160
- Montesano, S., see Trojani, A. (1) 15–28
- Montillo, M., see Trojani, A. (1) 15–28
- Morin, P. Jr, see Odjéle, A. (6) 245–252
- Morin, P. Jr, Editorial: MiRNAs in Cancer: Non-coding RNAs as Appealing Bio-markers for Malignancy (6) 227–228

- Morra, E., see Trojani, A. (1) 15–28  
 Morris, R., see Chatterjee, M. (2,3) 59–73  
 Motoyama, S., see Minamiya, Y. (4) 139–146  
 Munkarah, A., see Chatterjee, M. (2,3) 59–73  
 Mura, M., see Trojani, A. (1) 15–28
- Nefsky, B., see Liang, H. (4) 161–171  
 Nichelatti, M., see Trojani, A. (1) 15–28  
 Nitti, D., see Agostini, M. (2,3) 89–98  
 Norton, P.A., see Liang, H. (4) 161–171
- Odjélé, A., D. Charest and P. Jr Morin, miRNAs as important drivers of glioblastomas: a no-brainer? (6) 245–252  
 Ogawa, J., see Minamiya, Y. (4) 139–146  
 Orlacchio, A., see Trojani, A. (1) 15–28
- Paiva, B.S.R., see Paiva, C.E. (5) 209–217  
 Paiva, C.E., S.V. Serrano, B.S.R. Paiva, C. Scapulatempo-Neto, F.A. Soares, S.R. Rogatto and M.E.A. Marques, Absence of TGF- $\beta$ RII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors (5) 209–217  
 Panda, K., see Khanra, K. (4) 155–160  
 Paunović, I., see Marečko, I. (1) 49–58  
 Peng, J., see Lu, Y. (5) 219–226  
 Poulsen, H.S., see Bondgaard, A.-L.R.Ø. (2,3) 123–128  
 Poulsen, T.T., see Bondgaard, A.-L.R.Ø. (2,3) 123–128  
 Prins, A.M., see Lodewijk, L. (6) 229–238
- Qi, Z.-T., see Wang, W. (1) 29–39
- Rachagani, S., see Baine, M.J. (1) 1–14  
 Ren, H., see Wang, W. (1) 29–39  
 Ren, W.-J., see Wang, F. (6) 259–267  
 Ricci, F., see Trojani, A. (1) 15–28  
 Robichaud, G.A., see Harquail, J. (6) 269–280  
 Rogatto, S.R., see Paiva, C.E. (5) 209–217
- Saccani, A., see Agostini, M. (2,3) 89–98  
 Saito, H., see Minamiya, Y. (4) 139–146  
 Sand, D., see Sand, M. (6) 253–257  
 Sand, M., D. Sand, P. Altmeyer and F.G. Bechara, MicroRNA in non-melanoma skin cancer (6) 253–257  
 Sarkar, R., see Khanra, K. (4) 155–160  
 Sasson, A.R., see Baine, M.J. (1) 1–14  
 Savin, S., see Marečko, I. (1) 49–58  
 Scapulatempo-Neto, C., see Paiva, C.E. (5) 209–217  
 Scarpati, B., see Trojani, A. (1) 15–28  
 Scibior-Bentkowska, D., see Kim, D.C. (2,3) 75–88  
 Serrano, S.V., see Paiva, C.E. (5) 209–217  
 Shah, J.P., see Chatterjee, M. (2,3) 59–73  
 Shu, G.-S., L.-P. Yang, Z.-L. Yang and S. Jiang, Expression of CDC6 and GDF-9 and their clinicopathological significances in benign and malignant lesions of the gallbladder (2,3) 107–114  
 Skov, B.G., see Bondgaard, A.-L.R.Ø. (2,3) 123–128  
 Smith, L.M., see Baine, M.J. (1) 1–14  
 Soares, F.A., see Paiva, C.E. (5) 209–217  
 Sonmez, M., see Mentese, A. (5) 191–195  
 Stenman, U.-H., see K. (4) 173–181  
 Stražičar, M., see Tajnik, M. (5) 197–208  
 Sumer, A.U., see Mentese, A. (5) 191–195  
 Sun, G.-P., see Wang, F. (6) 259–267  
 Sun, R.P., see Liu, H.Y. (2,3) 115–121
- Tainsky, M.A., see Chatterjee, M. (2,3) 59–73  
 Tajnik, M., M. Stražičar, M. Volavšek, E. Boštjančič and D. Glavač, BBC3 is down-regulated with increased tumor size independently of p53 expression in head and neck cancer (5) 197–208  
 Takahashi, N., see Minamiya, Y. (4) 139–146  
 Tan, W., see Feng, X. (2,3) 99–106  
 Tao, Q.-Y., see Wang, W. (1) 29–39  
 Tatić, S., see Marečko, I. (1) 49–58  
 Tedeschi, A., see Trojani, A. (1) 15–28  
 Thorat, M.A., see Kim, D.C. (2,3) 75–88  
 Trojani, A., B. Di Camillo, A. Tedeschi, M. Lodola, S. Montesano, F. Ricci, E. Vismara, A. Greco, S. Veronese, A. Orlacchio, S. Martino, C. Colombo, M. Mura, M. Nichelatti, A. Colosimo, B. Scarpati, M. Montillo and E. Morra, Gene expression profiling identifies *ARSD* as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia (1) 15–28
- Us Altay, D., see Mentese, A. (5) 191–195
- Valk, G.D., see Lodewijk, L. (6) 229–238  
 Vasiljević, N., see Kim, D.C. (2,3) 75–88  
 Veronese, S., see Trojani, A. (1) 15–28  
 Vismara, E., see Trojani, A. (1) 15–28  
 Volavšek, M., see Tajnik, M. (5) 197–208  
 Vriens, M.R., see Lodewijk, L. (6) 229–238
- Wang, D., see Wang, Y. (4) 129–137  
 Wang, F., G.-P. Sun, Y.-F. Zou, J.-Q. Hao, F. Zhong and W.-J. Ren, MicroRNAs as promising biomarkers for gastric cancer (6) 259–267

- Wang, H., see Feng, X. (2,3) 99–106  
Wang, L., see Wang, Y. (4) 129–137  
Wang, M., see Liang, H. (4) 161–171  
Wang, P., see Wang, Y. (4) 129–137  
Wang, W., H. Ren, L.-J. Zhao, Y. Wang, Q.-Y. Tao, M.A. Feitelson, P. Zhao and Z.-T. Qi, Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC (1) 29–39  
Wang, Y., see Wang, W. (1) 29–39  
Wang, Y., Y. Hu, D. Wang, K. Yu, L. Wang, Y. Zou, C. Zhao, X. Zhang, P. Wang and K. Ying, The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines (4) 129–137  
Wei, G., see Feng, X. (2,3) 99–106  
Wu, K., see Kim, D.C. (2,3) 75–88  
Xu, Q., F. Xue, B. Yuan, L. Zhang, J. Li and Z. He, The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population (4) 147–153  
Xu, Y., see Lu, Y. (5) 219–226  
Xue, F., see Xu, Q. (4) 147–153  
Yang, L.-P., see Shu, G.-S. (2,3) 107–114  
Yang, Z.-L., see Shu, G.-S. (2,3) 107–114  
Ye, S., see Feng, X. (2,3) 99–106  
Ying, K., see Wang, Y. (4) 129–137  
Yu, K., see Wang, Y. (4) 129–137  
Yuan, B., see Xu, Q. (4) 147–153  
Zavagno, G., see Agostini, M. (2,3) 89–98  
Zhang, L., see Xu, Q. (4) 147–153  
Zhang, X., see Wang, Y. (4) 129–137  
Zhang, X.Y., see Liu, H.Y. (2,3) 115–121  
Zhang, Y., see Feng, X. (2,3) 99–106  
Zhao, C., see Wang, Y. (4) 129–137  
Zhao, L.-J., see Wang, W. (1) 29–39  
Zhao, P., see Wang, W. (1) 29–39  
Zhong, F., see Wang, F. (6) 259–267  
Zhou, Y., see Feng, X. (2,3) 99–106  
Zou, Y., see Wang, Y. (4) 129–137  
Zou, Y.-F., see Wang, F. (6) 259–267